已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Abstract 765: Multiple signalling pathways are active in BRAF/NRAS wild type melanomas

作者
Zizhen Ming,Su Yin Lim,Richard F. Kefford,Helen Rizos
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:78 (13_Supplement): 765-765
标识
DOI:10.1158/1538-7445.am2018-765
摘要

Abstract In the last five years, the treatment of advanced melanoma has been revolutionised by the introduction of selective kinase inhibitors and immunotherapy. Selective inhibition of the mitogen activated protein kinase (MAPK) pathway has significantly improved the survival of patients with BRAFV600-mutant melanoma, and combination MEK and CDK4 inhibition is currently being trialed in patients with NRAS-mutant melanoma. Almost a quarter of all melanomas, however, are wild type for BRAF and NRAS and have no known actionable mutations. Currently, patients with wild type melanoma are treated with immunotherapies, which produce prolonged responses, but only in a small subset of patients. Overall, the prognosis for patients with wild type melanomas remains poor, and there is an urgent need to establish better therapeutic strategies for these patients. In order to define new therapeutic targets in BRAF/NRAS wild type melanoma, we sought to characterize the key proliferative and survival pathways in wild type melanomas. Wild type (n=14) and BRAFV600 (n=7) melanomas were treated with the MEK inhibitor trametinib at increasing doses from 0.5nM to 5000nM for 72h and sensitivity to MEK inhibition was assessed using viability assays. Signaling pathway activity in response to trametinib (10nM, 24h) was also examined in our panel of melanoma cells using the Human Phospho-Kinase Antibody Array (R&D Systems), which detects 43 different phosphorylated kinases. As expected, BRAFV600 melanomas were exquisitely sensitive to trametinib treatment (IC50=0.8-2.4nM). We also found that although a subset of BRAF/NRAS wild type melanomas (5/14; 36%) were sensitive to trametinib (IC50 0.5-4.9nM), the majority of these melanoma cells (9/14; 64%) were resistant to trametinib (IC50 10.5-264.8nM). Analysis of kinase activation status revealed little difference in signaling pathway activity between the sensitive and resistant wild type melanomas at baseline. Resistant wild type melanomas had higher activity of STAT3 compared to the sensitive cell lines. However, all these wild type melanomas showed variable activation of multiple signaling pathways that were not active in BRAFV600 melanomas. Specifically, at baseline, wild type melanomas showed pronounced activation of the JNK and p38 MAPK pathways, the FAK/Src pathway (i.e. FAK, Lck, Lyn, Fgr and Yes), the epidermal growth factor receptor tyrosine kinase and β-catenin compared to BRAFV600 melanomas. Activation of multiple signaling pathways in wild type melanomas may contribute to innate resistance or limit the efficacy of MEK inhibition, and we are currently exploring the impact of these pathways on the survival and MEK dependence of wild type melanomas. Citation Format: Zizhen Ming, Su Yin Lim, Richard F. Kefford, Helen Rizos. Multiple signalling pathways are active in BRAF/NRAS wild type melanomas [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 765.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
zmf完成签到 ,获得积分10
刚刚
zhr发布了新的文献求助30
1秒前
领导范儿的应助被SD512T采纳,获得10
1秒前
Akim的应助被qiying采纳,获得10
1秒前
汉堡包的应助被LH采纳,获得10
3秒前
luotao完成签到,获得积分10
3秒前
隐形静芙完成签到 ,获得积分10
4秒前
DongZ发布了新的文献求助10
5秒前
6秒前
司纤户羽完成签到 ,获得积分10
6秒前
齐欢完成签到,获得积分10
6秒前
zheng完成签到 ,获得积分10
6秒前
机智的嘻嘻完成签到 ,获得积分10
6秒前
7秒前
春日桑完成签到 ,获得积分10
9秒前
团宝妞宝完成签到,获得积分10
9秒前
喂喂喂是谁完成签到,获得积分10
10秒前
微笑大象完成签到,获得积分10
10秒前
风趣的雨灵完成签到,获得积分10
10秒前
李博宇完成签到,获得积分10
11秒前
11秒前
今后的应助被超级的水绿采纳,获得10
12秒前
解酒完成签到 ,获得积分10
12秒前
12秒前
平常迎天的应助被学术混子采纳,获得100
15秒前
CipherSage的应助被richardhipower采纳,获得10
15秒前
安静的猴子完成签到 ,获得积分10
15秒前
云梦泽完成签到 ,获得积分10
15秒前
zhr发布了新的文献求助10
17秒前
闫栋完成签到 ,获得积分10
17秒前
简单十三完成签到,获得积分10
17秒前
紫薇的舔狗完成签到 ,获得积分10
18秒前
1499yqq完成签到 ,获得积分10
18秒前
彼岸完成签到,获得积分10
18秒前
纯情的匕完成签到 ,获得积分10
18秒前
19秒前
李博宇发布了新的文献求助10
20秒前
LH发布了新的文献求助10
20秒前
汉堡包的应助被喂喂喂是谁采纳,获得20
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189866
求助须知:如何正确求助?哪些是违规求助? 9577019
关于积分的说明 21851254
捐赠科研通 7787798
什么是DOI,文献DOI怎么找? 3435795
关于科研通互助平台的介绍 2559856
邀请新用户注册赠送积分活动 2482699